Stilla Technologies SAS

Stilla Technologies SAS develops innovative digital polymerase chain reaction (dPCR) solutions, enhancing precision in DNA quantification for research and clinical applications. Founded in 2013 in Paris, France, Stilla Technologies SAS focuses on digital PCR solutions, including its flagship Nio® platform. The company has completed four funding rounds, with the most recent round being a VENTURE DEBT of EUR 31. 3 mn on November 23, 2021, led by Casdin Capital and the European Investment Bank, among others.

The founders, Charles Baroud and Clément Gay, have a history of entrepreneurship in tech and biotech sectors, contributing to the company’s innovative approach. Under the leadership of CEO Philippe Mourere, Stilla has established itself with a strong presence in the global market. Stilla Technologies specializes in advanced digital polymerase chain reaction (dPCR) solutions through its flagship product, the Nio® system, which enables accurate DNA quantification across various applications, including oncology and pathogen detection. The Nio® platform is capable of processing up to 768 samples in an 8-hour workday, with user-friendly software and continuous loading capabilities.

Stilla serves clients including hospitals, research institutions, and pharmaceutical companies across Europe, North America, and Asia, providing essential technology for mutation detection and genetic analysis. In the most recent fiscal year 2022, Stilla Technologies generated revenue of EUR 6,837,455. 10 with an EBITDA of EUR -13,362,308. The company earns revenue through direct sales of the Nio® digital PCR systems, consumables, and specialized assay kits to academic institutions and biotech firms, establishing a strong B2B framework.

Customers frequently return for additional products, reinforcing ongoing relationships vital for business continuity. In November 2021, Stilla Technologies SAS raised EUR 31. 3 mn in VENTURE DEBT funding aimed at expanding its global commercial footprint and developing a next-generation digital PCR platform. The company plans to introduce new products into the market and enhance its presence in existing and new geographic regions.

Specific markets targeted for expansion include North America and Asia, with plans to solidify their impact by 2023. The funding will be utilized to support these initiatives, reflecting Stilla's commitment to innovation and market growth.